Rus En Es
Main / Company's news / Venezuela receives insulins and pen injectors produced by GEROPHARM

Venezuela receives insulins and pen injectors produced by GEROPHARM

20 July 2023

On July 19, a large shipment of insulins produced by GEROPHARM (Russia) arrived to Venezuela. The shipment was made under the manufacturer’s long-term contract with the Government of Venezuela and partnering companies ESPROMED BIO and CORPOVEX.

Since 2019, GEROPHARM has been continuously supplying insulins to Venezuela, which are vital for diabetic patients. The current shipment includes more than 1.1 mln packages of rapid- and intermediate-acting recombinant human insulins Rinsulin® R and Rinsulin® NPH. This amount is sufficient to cover the needs of all patients in the country who require insulin treatment for a period of up to three months.

In addition to insulins, GEROPHARM also sent more than 40,000 modern reusable pen injectors, which allow for a more comfortable and safer use of the medicinal products. The lightweight and heat-resistant aluminium pen injector body ensures a smooth temperature profile in the insulin cartridge. This is critical to ensure the safety and efficacy of product administration.

The cooperation between the government and business sectors of Russia and Venezuela is essential to the safety of patients with diabetes mellitus. Today, we are the sole supplier of insulins for the country’s public sector. We feel responsible for people’s health and, despite the difficult international situation, implement all our commitments,” says Pyotr Rodionov, General Director of GEROPHARM.


According to official data, there are 2 mln patients with diabetes mellitus in Venezuela. Many of them need daily insulin injections (IDF Diabetes Atlas).

GEROPHARM is an international and dynamic biotechnological company with all the most demanded insulins in its portfolio. The company produces recombinant human insulins and ultra-rapid-, rapid-, intermediate- and long-acting insulin analogues. Six more insulin products are currently under development.

All stages of insulin production, including molecule biosynthesis, are carried out at the company’s own production facilities in Russia in full compliance with GxP quality standards.

ESPROMED BIO C.A. is a state-owned company engaged in the development and manufacturing of biological medicinal products. The company operates under the auspices of the Ministry of the Popular Power for Health of the Bolivarian Republic of Venezuela and produces vaccines, monoclonal antibodies, erythropoietins, interferons, and other biological products.

You are a health care professional?

Go up